The designation allows Diakonos to expedite development and review of the organization’s dendritic cell vaccine technology for pancreatic cancer, according to a July 15 news release from the company. Diakonos has also applied the DCV technology to a vaccine for treating glioblastoma.
Daniel Von Hoff, MD, has been named to the Diakonos’ scientific advisory board and will advise the clinical development process of the pancreatic cancer vaccine.
Leave a Reply